Home
About +
Our Story
Meet the Team
FAQs
Our Science +
Inhaled IFN-β
Clinical Trials
Publications
Factsheets
Investors +
Investor Overview
Investor News
Reports & Presentations
Major Shareholders & Advisers
Shareholder Information
Corporate Governance
TR-1/Options Press Release Archive
Careers
Contact
Home
About
Our Science
Investors
Careers
Contact
Back
Our Story
Meet the Team
FAQs
Back
Inhaled IFN-β
Clinical Trials
Publications
Factsheets
Back
Investor Overview
Investor News
Reports & Presentations
Major Shareholders & Advisers
Shareholder Information
Corporate Governance
TR-1/Options Press Release Archive
Investors
Investor News
Subscribe to news
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
Shares Admitted to Trading on Asset Match
8th May 2025
John Bradshaw appointed as independent Non-Executive Director
29th April 2025
Update on trading post cancellation
3rd April 2025
Result of General Meeting, Cancellation and Re-registration
28th March 2025
Proposed cancellation of admission of Ordinary Shares to trading on AIM
11th March 2025
Martin Murphy appointed as Non-Executive Director
16th January 2025
Result of General Meeting and Total Voting Rights
16th January 2025
£18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections
15th January 2025